Evidence map›Paper›PMID 41799507›Full record

ArticleOncology research2026

Shulong Zhang, Yijun Zhao, Li Geng, Feihong Song, Li Feng, Jun Jiang, Qianqian Cai, Fei Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shulong ZhangDepartment of General Surgery, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, 200031, China.
Yijun ZhaoDepartment of the Third Ward of Special Treatment, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China.
Li GengDepartment of the Third Ward of Special Treatment, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China.
Feihong SongDepartment of the Third Ward of Special Treatment, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China.
Li FengEndoscopy Center, Minhang Hospital, Fudan University, No. 170 Xinsong Road, Shanghai, 201199, China.
Jun JiangEndoscopy Center, Minhang Hospital, Fudan University, No. 170 Xinsong Road, Shanghai, 201199, China.
Qianqian CaiShanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Fei FanDepartment of the Third Ward of Special Treatment, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly lethal malignancy driven by both intrinsic oncogenic pathways and immune microenvironmental regulation. Emerging evidence suggests that Methods: Bioinformatics analyses of the GSE41804 and Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) datasets were used to identify hub genes. Functional assays assessed the impact of Results: Eight prognostic signature genes were identified, with Conclusion:

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsWnt Signaling PathwayAnimalsbeta CateninCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansOrganoidsPrognosisbeta CateninDNASE1L3; Wnt/β-catenin signaling pathwayHepatocellular carcinomaorganoid modelstumor growth

Identifiers

PMID41799507
PMCPMC12963676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.